Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 7/20 | 0.35 |
| ▸ | THRA | P10827 | 5/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295275 | 0.89 | ATM (0.38) | EGLN1ATMTHRBTHRAGCGR | |
| SCHEMBL4299059 | 0.81 | KDM4E (0.37) | EGLN1THRBTHRA | |
| SCHEMBL4540014 | 0.79 | EGLN1 (0.36) | EGLN1ATMTHRBTHRAHIF1A | |
| SCHEMBL3978301 | 0.76 | THRB (0.37) | THRBTHRA | |
| SCHEMBL4263531 | 0.75 | MAPT (0.43) | EGLN1 | |
| SCHEMBL4300846 | 0.75 | MAPT (0.47) | EGLN1THRBTHRAHIF1A | |
| SCHEMBL3984716 | 0.75 | EGLN1 (0.38) | EGLN1THRBTHRAHIF1A | |
| SCHEMBL3986363 | 0.72 | THRB (0.37) | THRBTHRA | |
| SCHEMBL3990474 | 0.69 | KDM4E (0.47) | EGLN1THRBHIF1A | |
| SCHEMBL5619110 | 0.68 | THRB (0.65) | THRBTHRAHIF1ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| EP-2024336-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128492-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | EGLN1 2905/4885ATM 3307/4885THRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.